NCT03674502View on ClinicalTrials.gov

Safety of ADU-1604 in Adults With Metastatic Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

August 9, 2019

Study Completion Date

August 9, 2019

Conditions
Metastatic Melanoma
Interventions
DRUG

ADU-1604

anti-CTLA-4 monoclonal antibody

Trial Locations (5)

13885

Hôpital de la Timone, Marseille

28034

Hospital Universitario Ramon y Cajal, Madrid

41009

Hospital Universitario Virgen Macarena, Seville

75010

Hospital Saint Louis, Paris

94805

Gustave- Roussy Institute, Villejuif

Sponsors
All Listed Sponsors
lead

Aduro Biotech, Inc.

INDUSTRY

NCT03674502 - Safety of ADU-1604 in Adults With Metastatic Melanoma | Biotech Hunter | Biotech Hunter